Magellan Rx—Magellan Health’s (Magellan) fully-integrated pharmacy benefit manager (PBM) offering —and Amgen are forming a multi-year partnership to improve consumer care for chronic and difficult-to-treat conditions. Amgen is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California.
The collaboration will focus on the conditions of osteoporosis and migraines, considered two of the more difficult-to-treat conditions in health care. According to statements from Magellan leadership, the two organizations have a unique testing opportunity that can offer real-world evidence, which can in turn be used to create value and insights for health care consumers across health care systems. Pertaining to osteoporosis, the project aims to improve disease management for individuals recovering from bone fracture, as well as determine if identifying and intervening with high-risk individuals with osteoporosis will yield improved health outcomes and reduced health care system costs. Pertaining to migraines, the collaborative effort will work to identify the unmet needs of individuals living with migraines, seeking new ways to improve their treatment—especially without the use of opioids.
Magellan Health, Inc. engages in the health care management business in the United States. The company’s health care segment engages in the management of behavioral health care services and employee assistance program services.
This was reported by AJMC on December 14, 2018.
Contact Information: Amgen Corporate Headquarters, One Amgen Center Drive, Thousand Oaks, California 91320; (805) 447-1000; Website: www.amgen.com
Contact Information: Magellan Health, Inc., 4800 North Scottsdale Road Suite 4400, Scottsdale, Arizona 85251: (602) 572-6050; Website: www.magellanhealth.com